The study, published in JAMA, showed that muvalapin lowered levels by up to 85.8% of adults with elevated levels of the lipid. In the trial, participants who received the highest dose of muvalapin showed the most significant reduction in lipoprotein(a) levels, compared to a placebo.
The drug was administered once daily for 12 weeks, with reductions in lipoprotein(a) observed across all three tested doses. The reduction ranged from 47.6% at the lowest dose to 85.5% at the highest.
Secondary endpoints of the trial also showed that muvalapin lowered apolipoprotein B, a protein associated with heart disease, at all tested doses. The drug’s safety profile was consistent with the placebo, with few treatment-related side effects.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.